Disposition of Caspofungin, a Novel Antifungal Agent, in Mice, Rats, Rabbits, and Monkeys
Authors:
Open Access
- 1 April 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (4) , 1272-1280
Abstract
The metabolism, excretion, and pharmacokinetics of caspofungin (Cancidas; Merck & Co., Inc.) were investigated after administration of a single intravenous dose to mice, rats, rabbits, and monkeys. Caspofungin had a low plasma clearance (0.29 to 1.05 ml/min/kg) and a long terminal elimination half-life (11.7 h to 59.7 h) in all preclinical species. The elimination kinetics of caspofungin were multiphasic and displayed an initial distribution phase followed by a dominant β-elimination phase. The presence of low levels of prolonged radioactivity in plasma was observed and was partially attributable to the chemical degradation product M0. Excretion studies with [3H]caspofungin indicated that the hepatic and renal routes play an important role in the elimination of caspofungin, as a large percentage of the radiolabeled dose was recovered in urine and feces. Excretion of radioactivity in all species studied was slow, and low levels of radioactivity were detected in daily urine and fecal samples throughout a prolonged collection period. Although urinary profiles indicated the presence of several metabolites (M0, M1, M2, M3, M4, M5, and M6), the majority of the total radioactivity was associated with the polar metabolites M1 [4(S)-hydroxy-4-(4-hydroxyphenyl)-l-threonine] and M2 [N-acetyl-4(S)-hydroxy-4-(4-hydroxyphenyl)-l-threonine]. Caspofungin was thus primarily eliminated by metabolic transformation; however, the rate of metabolism was slow. These results suggest that distribution plays a prominent role in determining the plasma pharmacokinetics and disposition of caspofungin, as very little excretion or biotransformation occurred during the early days after dose administration, a period during which concentrations in plasma fell substantially. The disposition of caspofungin in preclinical species was similar to that reported previously in humans.Keywords
This publication has 20 references indexed in Scilit:
- CaspofunginClinical Infectious Diseases, 2003
- Caspofungin: first approved agent in a new class of antifungalsExpert Opinion on Pharmacotherapy, 2003
- Successful treatment of Candida krusei infection with caspofungin acetate: A new antifungal agentCritical Care Medicine, 2003
- Caspofungin in Combination with Itraconazole for the Treatment of Invasive Aspergillosis in HumansClinical Infectious Diseases, 2002
- Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy MenAntimicrobial Agents and Chemotherapy, 2002
- Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal CandidiasesAntimicrobial Agents and Chemotherapy, 2002
- Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan AntigenemiaAntimicrobial Agents and Chemotherapy, 2002
- CaspofunginDrugs of Today, 2002
- Compartmental Pharmacokinetics of the Antifungal Echinocandin Caspofungin (MK-0991) in RabbitsAntimicrobial Agents and Chemotherapy, 2001
- Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detectionAnalytica Chimica Acta, 1997